NCT04276376
Clinical Trial Detail
Contact
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| NCT ID | NCT04276376 |
| Title | Efficacy and Safety of the Combination of Rucaparib (PARP Inhibitor) and Atezolizumab (Anti-PD-L1 Antibody) in Patients With DNA Repair-deficient or Platinum-sensitive Solid Tumors (ARIANES) |
| Acronym | ARIANES |
| Recruitment | Terminated |
| Gender | both |
| Phase | Phase II |
| Variant Requirements | Yes |
| Sponsors | Gustave Roussy, Cancer Campus, Grand Paris |
| Indications | |
| Therapies | |
| Age Groups: | senior | adult |
| Covered Countries | FRA |
CKB BOOST